

Summary of Product Characteristics

1 NAME OF THE MEDICINAL PRODUCT

Metronidazole 5 mg/ml solution for infusion

2 QUALITATIVE AND QUANTITATIVE COMPOSITION

1 ml of solution contains 5 mg of metronidazole

100 ml of solution contain 500 mg of metronidazole

Excipients:

1 ml solution contains

Sodium chloride 7.4 mg

Disodium phosphate dodecahydrate 1.5 mg

Electrolyte content (per 100 ml):

Sodium 14 mmol

Chloride 13 mmol

For a full list of excipients, see section 6.1

3 PHARMACEUTICAL FORM

Solution for infusion

Clear, colourless or slightly yellowish aqueous solution

4 CLINICAL PARTICULARS

4.1 Therapeutic indications

Treatment and prophylaxis of infections caused by metronidazole susceptible microorganisms (mainly anaerobic bacteria). Metronidazole is indicated in adults and children for the following indications when caused by bacteria susceptible to metronidazole:

- infections of the central nervous system-(e.g. brain abscess, meningitis)
- infections of lung and pleura (e.g. necrotising pneumonia, aspiration pneumonia, lung abscess)
- endocarditis
- infections in the gastrointestinal tract and the abdominal area (e.g. peritonitis, liver abscess, postoperative infections after colonic and rectal surgery, purulent diseases in the abdominal and pelvic cavities)
- gynaecologic infections (e.g. endometritis, after hysterectomy or caesarean section, puerperal pyrexia, septic abortion)
- infections in the ear-nose-throat and tooth-mouth-jaw regions (e.g. necrotising ulcerative gingivostomatitis)
- bone and joint infections (e.g. osteomyelitis)
- gas gangrene
- septicaemia with thrombophlebitis.

In a mixed aerobic and anaerobic infection, antibiotics appropriate for the treatment of the aerobic infection should be used in addition to Metronidazole 5mg/ml.

A prophylactic use may be indicated prior to operations with a high risk of anaerobic infections (gynaecologic and intra-abdominal operations).

Consideration should be given to official guidance on the appropriate use of antibacterial agents.

4.2 Posology and method of administration

Posology

The dosage is adjusted according to the patient's individual response to therapy, her/his age and body weight and according to nature and severity of the disease.

The following dosage guidelines should be followed:

Adults and adolescents:

Treatment of anaerobic infections:

Usually a single dose of 1500 mg (300 ml) is given on the first day of treatment followed by 1000 mg (200ml) given as single doses on the subsequent days.

Alternatively, 500 mg (100 ml) may be given every 8 hours. If medically indicated a loading dose of 15mg/kg body weight (BW) may be given at the beginning of treatment.

The duration of therapy is dependent on the effect of the treatment. In most cases a treatment course of 7 days will be sufficient. If clinically indicated, treatment may be continued beyond this time. (See also section 4.4.)

Prophylaxis against post-operative infection caused by anaerobic bacteria:

500 mg, with administration completed approximately one hour before surgery. The dose is repeated after 8 and 16 hours.

Paediatric population

Treatment of anaerobic infections:

- Children > 8 weeks to 12 years of age:

The usual daily dose is 20 – 30 mg per kg BW per day as a single dose or divided into 7.5 mg per kg BW every 8 hours. The daily dose may be increased to 40 mg per kg BW, depending on the severity of the infection.

- Children < 8 weeks of age:

15 mg per kg BW as a single dose daily or divided into 7.5 mg per kg BW every 12 hours.

- In newborns with a gestation age < 40 weeks,

accumulation of metronidazole can occur during the first week of life; therefore the concentrations of metronidazole in serum should preferably be monitored after a few days therapy.

Duration of treatment is usually 7 days.

Prophylaxis against postoperative infections caused by anaerobic bacteria:

- Children < 12 years:

20 – 30 mg/kg BW as a single dose given 1 – 2 hours before surgery

- Newborns with a gestation age <40 weeks:

10 mg/kg BW as a single dose before surgery

Patients with renal insufficiency

No dose reduction is required, see section 5.2.

In patients undergoing haemodialysis the conventional dose of metronidazole should be scheduled after haemodialysis on dialysis days to compensate the escape of metronidazole during the procedure.

Patients with hepatic insufficiency

As serum half-life is prolonged and plasma clearance is delayed in severe hepatic insufficiency, patients with severe liver disease will require lower doses (see section 5.2).

Method of administration

Intravenous use.

The contents of one bottle are to be infused slowly i.v., i.e. 100 ml max. over not less than 20 minutes, but normally over one hour.

Metronidazole 5mg/ml can also be diluted before administration, adding the medicinal product to an i.v. vehicle solution such as 0.9 % sodium chloride or 5 % glucose infusion solution.

Concurrently prescribed antibiotics are to be administered separately.

4.3 Contraindications

Hypersensitivity to the active substance or other nitroimidazole derivatives or to any of the excipients listed in section 6.1.

4.4 Special warnings and precautions for use

Patients should be advised not to take alcohol during metronidazole therapy (see section 4.5).

In patients with severe liver damage or impaired haematopoiesis (e. g. granulocytopenia), metronidazole should only be used if its expected benefits clearly outweigh potential hazards.

Due to the risk of aggravation, metronidazole should also be used in patients with active or chronic severe peripheral and central nervous system diseases only if its expected benefits clearly outweigh potential hazards.

Convulsive seizures, myoclonus and peripheral neuropathy, the latter mainly characterized by numbness or paresthesia of an extremity, have been reported in patients treated with metronidazole. The appearance of abnormal neurological signs demands the prompt evaluation of the benefit/risk ratio of the continuation of therapy.

In the case of severe hypersensitivity reactions (e.g. anaphylactic shock), treatment with Metronidazole B. Braun 5 mg/ml must be discontinued immediately and established emergency treatment must be initiated by qualified healthcare professionals.

Severe persistent diarrhoea occurring during treatment or during the subsequent weeks may be due to pseudomembranous colitis (in most cases caused by *Clostridioides difficile*), see section 4.8. This intestinal disease, precipitated by the antibiotic treatment, may be life-threatening and requires immediate appropriate treatment. Anti-peristaltic medicinal products must not be given.

The duration of therapy with metronidazole or drugs containing other nitroimidazoles should not exceed 10 days. Only in specific elective cases and if definitely needed, the treatment period may be extended, accompanied by appropriate clinical and laboratory monitoring. Repeat therapy should be restricted as much as possible and to specific elective cases only. These restrictions must be observed strictly because the possibility of metronidazole developing mutagenic activity cannot be safely excluded and because in animal experiments an increase of the incidence of certain tumours has been noted.

Imbalances of the normal flora (fungal/bacterial overgrowth) and possible superinfections may occur, especially with prolonged metronidazole treatment or in immunocompromised patients.

Severe Cutaneous Adverse Reactions- Severe cutaneous adverse reactions (SCARs) including toxic epidermal necrolysis (TEN), Stevens-Johnson syndrome (SJS), drug reaction with eosinophilia and systemic symptoms (DRESS), and acute generalized exanthematous pustulosis (AGEP) have been reported with the use of metronidazole. Symptoms can be serious and potentially life threatening. If symptoms or signs of SCARs develop, discontinue Metronidazole injection immediately and institute appropriate therapy.

Prolonged therapy with metronidazole may be associated with bone marrow depression, leading to an impairment of haematopoiesis. Manifestations see section 4.8.

Blood cell counts should be carefully monitored during prolonged therapy.

Hepatotoxicity in patients with Cockayne Syndrome

Cases of severe hepatotoxicity/acute hepatic failure, including cases with a fatal outcome with very rapid onset after treatment initiation in patients with Cockayne syndrome have been reported with products containing metronidazole for systemic use. In

this population, metronidazole should not be used unless the benefit is considered to outweigh the risk and if no alternative treatment is available.

Liver function tests must be performed just prior to the start of therapy, throughout and after end of treatment until liver function is within normal ranges, or until the baseline values are reached. If the liver function tests become markedly elevated during treatment, the drug should be discontinued.

Patients with Cockayne syndrome should be advised to immediately report any symptoms of potential liver injury to their physician and stop taking metronidazole (see section 4.8).

This container contains a significant volume of air. To avoid the risk of air embolism, this product must not be administered by pressure infusion.

Special warnings/precautions regarding excipients

This medicinal product contains 322 mg sodium per 100 ml, equivalent to 16 % of the WHO recommended maximum daily intake of 2 g sodium for an adult.

Interference with laboratory tests:

Metronidazole interferes with the enzymatic-spectrophotometric determination of aspartate aminotransferase (AST), alanine aminotransferase (ALT), lactate dehydrogenase (LDH), triglycerides and glucose hexokinase resulting in decreased values (possibly down to zero).

Metronidazole has a high absorbance at the wavelength at which nicotinamide-adenine dinucleotide (NADH) is determined. Therefore elevated liver enzyme concentrations may be masked by metronidazole when measured by continuous-flow methods based on endpoint decrease in reduced NADH. Unusually low liver enzyme concentrations, including zero values, have been reported.

4.5 Interaction with other medicinal products and other forms of interaction

Interactions with other medicinal products

Drugs that prolong the QT interval

Prolongation of the QT interval has been reported, especially when metronidazole is administered together with drugs that have the potential to prolong the QT interval. QT interval prolongation and torsade de pointes have been reported with the coadministration of metronidazole and amiodarone or ciprofloxacin, respectively. It may be appropriate to monitor QT interval on the ECG if amiodarone or ciprofloxacin is used in combination with metronidazole. Patients treated on an outpatient basis should be advised to seek medical attention if they experience symptoms that could indicate the occurrence of torsade de pointes such as dizziness, palpitations, or syncope.

Barbiturates

Phenobarbital may increase the hepatic metabolism of metronidazole, reducing its plasma half life to 3 hours.

Busulfan

Coadministration with metronidazole may significantly increase the plasma concentrations of busulfan. The mechanism of interaction has not been described. Due to the potential for severe toxicity and mortality associated with elevated busulfan plasma levels, concomitant use with metronidazole should be avoided.

Carbamazepine

Metronidazole may inhibit the metabolism of carbamazepine and raise the plasma concentrations as a consequence.

Cimetidine

Concurrently administered cimetidine may reduce the elimination of metronidazole in isolated cases and subsequently lead to increased metronidazole concentrations in serum.

Coumarin derivatives

Concomitant treatment with metronidazole may potentiate the anticoagulant effect of these and increase the risk for bleeding as a consequence of decreased hepatic degradation. Dose adjustment of the anticoagulant can be necessary.

Cyclosporine

During simultaneous therapy with cyclosporine and metronidazole there is a risk for increased serum concentrations of cyclosporine. Frequent monitoring of cyclosporine and creatinine is required.

Disulfiram

Simultaneous administration of disulfiram may cause states of confusion or even psychotic reactions. Combination of both agents must be avoided.

Fluorouracil

Metronidazole inhibits the metabolism of concurrently administered fluorouracil, i.e. the plasma concentration of fluorouracil is increased.

Lithium

Caution is to be exercised when metronidazole is administered simultaneously with lithium salts, because under metronidazole therapy raised serum concentrations of lithium have been observed.

Mycophenolate mofetil

Substances that alter the gastrointestinal flora (e.g., antibiotics) may reduce the oral bioavailability of mycophenolic acid products. Close clinical and laboratory monitoring for evidence of diminished immunosuppressive effect of mycophenolic acid is recommended during concomitant therapy with anti-infective agents.

Phenytoin

Metronidazole inhibits the metabolism of concurrently administered phenytoin, i.e. the plasma concentration of phenytoin is increased. On the other hand, the efficacy of metronidazole is reduced when phenytoin is administered concurrently.

Tacrolimus

Coadministration with metronidazole may increase the blood concentrations of tacrolimus. The proposed mechanism is inhibition of hepatic tacrolimus metabolism via CYP 3A4. Tacrolimus blood levels and renal function should be checked frequently and the dosage adjusted accordingly, particularly following initiation or discontinuation of metronidazole therapy in patients who are stabilized on their tacrolimus regimen.

Other forms of interaction*Alcohol*

Intake of alcoholic beverages must be avoided during metronidazole therapy and up to 48h after administration of the medicinal product since adverse reactions such as dizziness and vomiting may occur (disulfiram-like effect).

4.6 Fertility, pregnancy and lactation*Pregnancy*

The safety of the use of metronidazole during pregnancy has not sufficiently been demonstrated. In particular, reports on the use during early pregnancy are contradictory. Some studies indicated an increased rate of malformations. In animal experiments metronidazole did not show teratogenic effects (see section 5.3).

During the first trimester, Metronidazole 5mg/ml should only be used to treat severe life-threatening infections, if there is no safer alternative. During the second and third trimester, Metronidazole 5mg/ml may also be used to treat other infections if its expected benefits clearly outweigh any possible risk.

Breast-feeding

Since metronidazole is secreted into breastmilk, nursing is to be interrupted during therapy. Also after the end of the therapy with metronidazole, nursing should not be resumed before another 2 – 3 days because of the prolonged half-life period of metronidazole.

Fertility

Animal studies have indicated a negative influence on the male reproductive system; however this was only seen at very high doses which were far in excess of the recommended dose for humans.

4.7 Effects on ability to drive and use machines

Even when used as directed, metronidazole may alter reactivity so far that the ability to drive or to use machinery is impaired. This holds true to still a higher degree at the beginning of treatment or in combination with alcohol intake.

4.8 Undesirable effects

Undesirable effects are mainly associated with prolonged use or high doses. The most commonly observed effects include nausea, abnormal taste sensations and the risk of neuropathy in case of long term treatment.

In the following listing, for the description of the frequencies of undesirable effects the following terms are used:

Very common: $\geq 1/10$

Common: $\geq 1/100$ to $< 1/10$

Uncommon: $\geq 1/1,000$ to $< 1/100$

Rare: $\geq 1/10,000$ to $< 1/1,000$

Very rare: $< 1/10,000$

Not known: (Frequency cannot be estimated from the available data)

Infections and infestations

Common: Fungal and bacterial superinfections

Rare: Pseudomembranous colitis, which may occur during or after therapy, manifesting as severe persistent diarrhoea. Details regarding emergency treatment see section 4.4.

Blood and lymphatic system disorders

Very rare: During therapy with metronidazole, decreases of leukocyte and platelet counts (granulocytopenia, agranulocytosis, pancytopenia and thrombocytopenia)

Not known: Leucopenia, aplastic anaemia.

During prolonged administration regular monitoring of blood cell counts is mandatory.

Immune system disorders

Rare: Severe acute systemic hypersensitivity reactions: anaphylaxis, up to anaphylactic shock.

Not known: Mild to moderate hypersensitivity reactions, e. g. skin reactions (see "*Skin and subcutaneous disorders*" below) angioedema.

Metabolism and nutrition disorders

Not known: Anorexia

Psychiatric disorders

Very rare: Psychotic disorders, including states of confusion, hallucination

Not known: Depression

Nervous system disorders

Very rare: Encephalopathy, headache, fever, drowsiness, dizziness, disturbances in sight and movement, vertigo, ataxia, dysarthria, convulsions.

Not known: Somnolence or insomnia, myoclonus, seizures, peripheral neuropathy manifesting as paraesthesia, tinnitus, hearing impairment, hearing loss (including sensorineural hearing loss), pain, furry sensation, and tingling in the extremities
Aseptic meningitis

If seizures or signs of peripheral neuropathy or encephalopathy appear, the attending doctor should be informed immediately.

Eye disorders

Very rare: Disturbance of vision, e.g. diplopia, myopia.

Not known: Oculogyric crisis, optic neuropathy/neuritis (isolated cases)

Cardiac disorders

Rare: ECG changes like flattening of T-wave

Gastro-intestinal disorders

Very rare: Pancreatitis

Not known: Vomiting, nausea, diarrhoea, glossitis and stomatitis, eructation with bitter taste, epigastric pressure, metallic taste, furred tongue.

Dysphagia (caused by central nervous effects of metronidazole)

Hepatobiliary disorders

Very rare: - Abnormal values of hepatic enzymes and bilirubin

- Hepatitis, jaundice

Cases of severe irreversible hepatotoxicity/acute liver failure, including cases with fatal outcomes with very rapid onset after initiation of systemic use of metronidazole, have been reported in patients with Cockayne Syndrome (see section 4.4).

Skin and subcutaneous tissue disorders

Very rare: Allergic skin reactions, e. g. pruritus, urticaria

Not known: Erythema multiforme, Toxic epidermal necrolysis (TEN), Stevens-Johnson Syndrome (SJS), drug reaction with eosinophilia and systemic symptoms (DRESS), acute generalized exanthematous pustulosis (AGEP) (see section 4.4)

Musculoskeletal and connective tissue disorders

Very rare: Arthralgia, myalgia

Renal and urinary disorders

Uncommon: Dark coloured urine (due to a metabolite of metronidazole)

General disorders and administration site conditions

Not known: Vein irritations (up to thrombophlebitis) after intravenous administration asthenia, fever

Paediatric population

Frequency, type and severity of adverse reactions in children are the same as in adults.

Reporting of suspected adverse reactions

Reporting suspected adverse reactions after authorisation of the medicinal product is important. It allows continued monitoring of the benefit/risk balance of the medicinal product. Healthcare professionals are asked to report any suspected adverse reactions via

HPRA Pharmacovigilance

Website: www.hpra.ie

4.9 Overdose

Symptoms

As signs and symptoms of overdose the undesirable effects described under section 4.8 may appear.

Treatment

There is no specific treatment or antidote that can be applied in the case of gross overdose of metronidazole. If required, metronidazole can be effectively eliminated by haemodialysis.

5 PHARMACOLOGICAL PROPERTIES

5.1 Pharmacodynamic properties

Pharmaco-therapeutic group: Anti-infectives for systemic use – imidazole derivatives

ATC Code: J01X D01

Mechanism of action

Metronidazole directly affects the DNA metabolism of anaerobic bacteria. Metronidazole itself is ineffective. It is a stable compound able to penetrate into microorganisms. Under anaerobic conditions nitroso radicals acting on DNA are formed from metronidazole by the microbial pyruvate-ferredoxin-oxidoreductase, with oxidation of ferredoxin and flavodoxin. Nitroso radicals form adducts with base pairs of the DNA, thus leading to breaking of the DNA chain and consecutively to cell death.

PK/PD relationship

The efficacy of metronidazole mainly depends on the quotient of the maximum serum concentration (c_{max}) and the minimum inhibitory concentration (MIC) relevant for the microorganism concerned.

Mechanisms of resistance to metronidazole

The mechanisms of metronidazole resistance are still understood only in part.

H. pylori resistance to metronidazole is caused by mutations of a gene that encodes NADPH nitroreductase. These mutations lead to an exchange of amino acids, rendering the enzyme inactive. Thus the step of activation of metronidazole to the active nitroso radical does not take place.

Strains of *Bacteroides* being resistant to metronidazole possess genes encoding nitroimidazole reductases converting nitroimidazoles to aminoimidazoles. Therefore the formation of the antibacterially effective nitroso radicals is inhibited.

There is full cross resistance between metronidazole and the other nitroimidazole derivatives (tinidazole, ornidazole, nimorazole).

The prevalence of acquired resistance of individual species may vary, depending on region and time. Therefore especially for the adequate treatment of severe infections specific local information regarding resistance should be available. If there is doubt about the efficacy of metronidazole due to the local resistance situation, expert advice should be sought. Especially in the case of severe infections or failure of treatment, microbiological diagnosis including determination of species of the microorganism and its susceptibility to metronidazole is required.

Susceptibility testing breakpoints

MIC (minimum inhibitory concentration) interpretive criteria for susceptibility testing have been established by the European Committee on Antimicrobial Susceptibility Testing (EUCAST) for metronidazole and are listed here:

https://www.ema.europa.eu/documents/other/minimum-inhibitory-concentration-mic-breakpoints_en.xlsx

List of susceptible and resistant organisms.

Source: Central Office for the Analysis of Resistance Data on Systemic Antibiotics) (Zentralstelle für die Auswertung von Resistenzdaten bei systemisch wirkenden Antibiotika; Z.A.R.S.) Germany, May 2024

Commonly susceptible species**Anaerobes**

Bacteroides fragilis
Clostridioides difficile
Clostridium perfringens°Δ
Gardnerella vaginalis°
Fusobacterium spp.°
Peptoniphilus spp.°
Peptostreptococcus spp.°
Porphyromonas spp.°
Prevotella spp.°
Veillonella spp.°

Other micro-organisms

Entamoeba histolytica°
Giardia lamblia°
Trichomonas vaginalis°

Species for which acquired resistance may be a problem**Gram-negative aerobes**

*Helicobacter pylori*¹

Inherently resistant organisms

All obligate aerobes

Gram-positive micro-organisms

Enterococcus spp.
Staphylococcus spp.
Streptococcus spp.

Gram-negative micro-organisms

Enterobacterales
Haemophilus spp.

° At the time of publication of these tables, no up-to-date data were available. In primary literature, standard reference books and therapy recommendations susceptibility of the respective strains is assumed.

¹ Resistance rate in patients previously treated only once is $\geq 50\%$.

Δ Only to be used in patients with allergy to penicillin

5.2 Pharmacokinetic properties*Absorption:*

Since Metronidazole 5mg/ml is infused intravenously the bioavailability is 100%.

Distribution:

Metronidazole is widely distributed in body tissues after injection. Metronidazole appears in most body tissues and fluids including bile, bone, cerebral abscess, cerebro-spinal fluid, liver, saliva, seminal fluid, and vaginal secretions, and achieves concentrations similar to those in plasma. It also diffuses across the placenta, and is found in breast milk of nursing mothers in concentrations equivalent to those in serum. Protein binding is less than 20 %, the apparent volume of distribution is 36 litres.

Biotransformation:

Metronidazole is metabolised in the liver by side-chain oxidation and glucuronide formation. Its metabolites include an acid oxidation product, a hydroxy derivative and glucuronide. The major metabolite in the serum is the hydroxylated metabolite, the major metabolite in the urine is the acid metabolite.

Elimination:

Approximately 80% of the substance is excreted in urine with less than 10% in the form of the unchanged drug substance. Small quantities are excreted via the liver. Elimination half-life is 8 (6-10) hours.

Paediatric population

See section 4.2.

Characteristics in special patient groups:

Renal insufficiency delays excretion only to an unimportant degree.

Delayed plasma clearance and prolonged serum half-life (up to 30 h) is to be expected in severe liver disease.

5.3 Preclinical safety data*Single-dose toxicity*

The lowest published toxic dose for intravenously administered Metronidazole has been referred to as 100 mg/kg BW.

Repeated dose toxicity

In dogs, toxic effects after repeated administration appeared in the form of ataxia and tremor. In investigations in monkeys a dose-dependent increase of hepatocellular degeneration was demonstrated after administration over one year.

Mutagenic and tumorigenic potential

Metronidazole has a mutagenic effect in bacteria after nitroreduction. Methodologically valid investigations did not give any findings suggesting a mutagenic effect on mammalian cells *in vitro* and *in vivo*. Investigations on lymphocytes of patients treated with metronidazole did not give any relevant finding indicating DNA damaging effects.

There are findings suggesting a tumorigenic effect on rats and mice. Of note, there was an increased rate of lung tumours in mice after oral administration. Epidemiology studies in humans have found no clear evidence that metronidazole is

carcinogenic; metronidazole is considered carcinogenic in animals when high dosages well above the therapeutic dosages are used and there are insufficient data to consider it as a human carcinogen.

Reproduction toxicity

No teratogenic or other embryotoxic effects have been observed in investigations with rats and rabbits.

After repeated administration of metronidazole over 26 – 80 weeks to rats, testicular and prostatic dystrophy has only been observed with high doses.

6 PHARMACEUTICAL PARTICULARS

6.1 List of excipients

Sodium chloride

Disodium phosphate dodecahydrate

Citric acid monohydrate

Water for injections

6.2 Incompatibilities

This medicinal product must not be mixed with other medicinal products except those mentioned in section 6.6.

6.3 Shelf life

Unopened

3 years.

After first opening the container

Once opened use immediately.

Unused contents must be discarded and not be stored for later use.

6.4 Special precautions for storage

Do not store above 25°C. Keep container in the outer carton in order to protect from light.

6.5 Nature and contents of container

The product is supplied in:

– bottles of low-density polyethylene, contents: 100 ml,
available in packs of 10 x 100 ml, 20 x 100 ml

Not all pack sizes may be marketed.

6.6 Special precautions for disposal of a used medicinal product or waste materials derived from such medicinal product and other handling of the product

No special requirements.

Any unused medicinal product or waste material should be disposed of in accordance with local requirements.

Other handling instructions:

For single use only. Discard container and any unused contents after use.

The product can be diluted in sodium chloride 0.9 % w/v or glucose 5 % w/v solutions for infusion. For dilution procedures the usual precautions of asepsis must be adhered to.

Only to be used if solution is clear and colourless or slightly yellowish and the container and its closure do not show visible signs of damage.

7 MARKETING AUTHORISATION HOLDER

B. Braun Melsungen AG
Carl-Braun-Straße 1
34212 Melsungen
Germany

8 MARKETING AUTHORISATION NUMBER

PA0736/002/001

9 DATE OF FIRST AUTHORISATION/RENEWAL OF THE AUTHORISATION

Date of first authorisation: 06 June 2001

Date of last renewal: 06 June 2006

10 DATE OF REVISION OF THE TEXT

June 2025